NanoTech Pharma

NanoTech Pharma is a private, pre-revenue biotech firm founded in 2005, specializing in next-generation drug delivery platforms. Its pipeline features multiple preclinical and early clinical programs across its three core technology pillars—liposomes, LNPs, and nanocrystals—targeting oncology, infectious diseases, liver disease, and mental health disorders. The company's strategy centers on leveraging its proprietary AccuLNP® and nanocrystal systems to enhance drug performance, overcome biological barriers, and enable precision medicine approaches.

Proprietary drug delivery platforms including: 1) Liposomes for multi-drug co-encapsulation; 2) AccuLNP® Lipid Nanoparticles (LNPs) with a library of novel ionizable lipids for nucleic acid delivery; 3) Nanocrystals for long-acting parenteral depot formulations.

NanoTech Pharma competes in the crowded and advanced field of drug delivery and nanomedicine. Major competitors include large-cap pharma with internal delivery technologies, specialized public biotechs like Moderna and BioNTech in LNPs, and companies like Pacira in sustained-release injectables. Differentiation relies on proprietary lipid libraries and formulation expertise.